Press release
Bispecific Antibody Competitive Landscape 2025: Providing Strategic Insights Into 180+ Companies and 250+ Drugs by DelveInsight
Bispecific Antibody Competitive Landscape
Get exclusive access to the only report analyzing 180+ companies & 250+ drugs in the bispecific antibody space. Download the Report - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bispecific Antibodies in Oncology Pipeline Summary
• Companies across the globe are diligently working toward developing novel Bispecific Antibody treatment therapies with a considerable amount of success over the years.
• The Bispecific Antibody pipeline report provides the total potential number of patients in the indications, such as Acute Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer, Small-cell Lung Cancer, Biliary Tract Cancer, Breast Cancer, Gastric Cancer/Esophageal Cancer, Pancreatic Cancer, Colorectal Cancer, and others.
• In the US, the population eligible for treatment with bispecific antibodies in oncology was estimated to be approximately 895K cases.
• Key bispecific antibodies in oncology companies, such as I-MAB Biopharma, BMS, AstraZeneca, BioNTech, Genmab, Compass Therapeutics, Innovent, Regeneron Pharmaceuticals, Aurigene Oncology, Curis, Akeso, Summit Therapeutics, Roche, Merus, Adimab, Creative Biolabs, Amgen, Zymeworks, Xencor, Novo Nordisk, MacroGenics, and others, are developing novel bispecific antibodies in oncology that can be available in the bispecific antibodies in oncology market in the coming years.
• Some of the key bispecific antibodies in oncology in the clinical trials include Givastomig, Volrustomig, BNT327, Acasunlimab, Rilvegostomig, CTX-009, IBI363, REGN5459, CA-170, Ivonescimab, Odronextamab, MCLA-129, MIM8, MGD024, COLUMVI, RYBREVANT, and others.
Discover pipeline therapies, collaborations, and market-shaping deals before your competitors. Request Your Free Sample Today - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Understanding Bispecific Antibodies
The Science Behind Antibodies
Immunoglobulins (antibodies [Abs]) are key proteins of the adaptive immune system that defend the body against infections and foreign agents. Among these, IgG molecules-consisting of two light and two heavy chains-play a dominant role, offering monospecific and bivalent activity. Traditionally, antibodies carry two identical antigen-binding sites. However, the advent of bispecific antibodies (BsAbs) has transformed this field, enabling the design of molecules that can target two distinct antigens simultaneously.
Bispecific Antibody Functionality
Bispecific antibodies have unlocked the ability to redirect cytotoxic T lymphocytes toward tumor cells by binding to CD3 receptors on T cells and tumor-associated antigens like CD19, CD20, HER2, BCMA, CEA, and EpCAM. This dual-targeting capability enhances tumor cell killing while activating the immune system's natural defenses.
Beyond oncology, bispecific antibodies are making headway in osteoporosis, hemophilia, Alzheimer's disease, and autoimmune disorders. For instance:
• ACE910 (Hemophilia A): Reduces bleeding rates by binding blood-clotting factors IX and X.
• Osteoporosis therapies: Target Wnt pathway regulators such as sclerostin and Dkk1 to promote bone growth.
• Neurodegenerative candidates: Combine transferrin receptor targeting with BACE1 inhibition to cross the blood-brain barrier and reduce amyloid peptide accumulation in Alzheimer's.
Advantages Over Monospecific Therapies
Bispecific antibodies represent a leap forward compared to conventional monoclonal antibodies. Key benefits include:
• Higher specificity and efficacy: Dual-target binding improves therapeutic potential.
• Cost-effectiveness: One BsAb can replace combination therapies with two monoclonals, lowering R&D and clinical trial costs.
• Resistance reduction: Targeting multiple receptors on a tumor cell mitigates the risk of resistance.
• Broader therapeutic reach: Expands treatment beyond oncology into inflammatory, autoimmune, and rare diseases.
Explore in-depth clinical, commercial, and scientific intelligence on the bispecific antibody market. Access the Report Now - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bispecific Antibody Competitive Landscape
• Janssen
• Amgen
• Akeso
• Zymeworks
• Roche
• IGM Biosciences
• MacroGenics
• Provention Bio
• Jiangsu Alphamab Biopharmaceuticals
• Sichuan Baili Pharmaceutical
• Regeneron Pharmaceuticals
• Boehringer Ingelheim
Bispecific Antibody Market Highlights: Strategic Collaborations & Developments
The "Bispecific Antibody - Competitive Landscape, 2025" report tracks significant business and scientific milestones shaping the global competitive field.
• LAVA Therapeutics N.V. & Merck & Co. (Jan 2024): Collaboration to study LAVA-1207 with KEYTRUDA® for metastatic prostate cancer.
• Biocytogen & Radiance Biopharma (Jan 2024): Exclusive license agreement on a novel HER2/TROP2 BsADC.
• Debiopharm & SunRock Biopharma (Jan 2024): Expanded licensing deal for HER3-EGFR bispecific ADCs.
• Pfizer & Seagen (Dec 2023): Pfizer's USD 43 billion acquisition doubled its oncology pipeline, including bispecifics.
• NAYA Biosciences & ONK (Dec 2023): Research partnership exploring NK cell combinations with FLEX-NKTM bispecifics.
• I-Mab (Nov 2023): Preclinical poster presentations on innovative CD4/4-1BB bispecifics at SITC.
• Cantai Therapeutics (Nov 2023): Formation of biotech company focused on cytokine-targeting BsAbs for autoimmune diseases.
• Lonza & ABL Bio (Apr 2023): Development and manufacturing partnership for BsAbs in oncology and neurodegeneration.
Learn how leading players like Amgen, Roche, AstraZeneca, and Regeneron are shaping the Bispecific Antibody market - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bispecific Antibody Marketed Therapies: Company Profiles
Janssen (Johnson & Johnson) - Amivantamab (RYBREVANT®)
• Target: EGFR & MET
• Indication: NSCLC with EGFR Exon 20 insertion mutations
• Significance: First FDA-approved therapy developed using Genmab's DuoBody® technology platform.
Amgen - Blinatumomab (BLINCYTO®)
• Target: CD19 & CD3 (BiTE® platform)
• Indications: Acute lymphoblastic leukemia, B-cell lymphomas
• Importance: First BiTE antibody; approved for multiple hematological malignancies with orphan drug designation.
Pipeline Therapies: Company Profiles
AstraZeneca - Gefurulimab
• Humanized bispecific antibody against C5 & albumin.
• Potential in autoimmune diseases through complement pathway inhibition.
Sichuan Baili Pharmaceutical - SI-B001
• Targets: EGFR & HER3
• Stage: Phase III
• Demonstrated strong tumor-killing efficacy in early trials.
Innovent Biologics - IBI322
• Targets: CD47 & PD-L1
• Stage: Phase II
• Dual immune activation mechanism for hematological and solid tumors.
IGM Biosciences - Imvotamab
• IgM-based CD20 x CD3 bispecific antibody.
• Offers stronger binding and reduced cytokine release compared to IgG bispecifics.
MacroGenics - MGD024
• Targets: CD123 × CD3 (DART® platform).
• Designed to minimize cytokine-release syndrome while maintaining anti-leukemia activity.
See where your organization stands in the global bispecific antibody pipeline landscape. Download report now - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bispecific Antibody Analytical Perspective by DelveInsight
The report goes beyond molecule-level science and provides commercial intelligence, including:
• Collaboration and licensing trends across industry and academia.
• Mergers & acquisitions reshaping the competitive landscape.
• Comparative company assessments by therapy area, clinical stage, and technology.
• Unmet needs and future opportunities for stakeholders.
Key Questions Addressed in Bispecific Antibody Pipeline Report
The report answers critical questions shaping the bispecific antibody market:
1. How many companies are developing bispecific antibody drugs?
2. What is the distribution of drugs across early, mid, and late-stage pipelines?
3. What are the key collaborations, licensing deals, and acquisitions driving innovation?
4. Which novel technologies are overcoming limitations of current antibody therapies?
5. What clinical studies are ongoing and what is their status?
6. Which drugs have received key designations and regulatory approvals?
Bispecific Antibody Future Outlook
The bispecific antibody market is global in scope, with R&D hubs in the United States, Europe, and Asia-Pacific. As regulatory frameworks evolve and new modalities emerge, BsAbs are poised to redefine cancer treatment and expand into autoimmune, neurodegenerative, and rare diseases.
DelveInsight forecasts that strategic collaborations, platform innovations, and expanding indications will drive substantial market growth in the coming decade.
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bispecific Antibody Competitive Landscape 2025: Providing Strategic Insights Into 180+ Companies and 250+ Drugs by DelveInsight here
News-ID: 4198496 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Bispecific
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Bispecific Drug Innovation - Creative Biolabs Concludes Its Journey at the 15th …
On September 5, Creative Biolabs successfully concluded its participation in the 15th Annual World Bispecific Summit.
New York, USA - September 10, 2024 - The summit brought together leading experts in the bispecific antibody [https://www.creative-biolabs.com/bsab/bispecific-antibody-bsab-development-service.htm] (BsAb) field from around the globe, offering attendees a rich platform to discuss cutting-edge developments and future directions.
Image: https://www.getnews.info/uploads/b7ea13d648fcb7917ba9b55571b2ba35.png
In recent years, this field has grown rapidly, becoming a focal point in biopharmaceutical research and development. A…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Global Bispecific Antibody Market Research Report Forecast 2017 to 2021Global Bi …
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Bispecific Antibody Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies.
The Global Bispecific Antibody Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Bispecific Antibody industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as…
Bispecific Antibodies Market - Global Industry Analysis 2024
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
